The International Liver Congress (ILC) 2016:  Rifaximin Use in Cirrhosis-Related Hepatological Disorders and New Perspectives

The International Liver Congress (ILC) 2016: Rifaximin Use in Cirrhosis-Related Hepatological Disorders and New Perspectives

May 31, 2016 at 8:27 AM 0 comments

Summary of the presentations on rifaximin from the Annual European Association for the Study of the Liver (EASL) meeting held in Barcelona, Spain, from 13th–17th April 2016 Caroline Charles Scilink Medical Writing, Biarritz, France. *Correspondence to scilink.mw@gmail.com Disclosure: The author has declared no conflicts of interest. Support: The publication ofRead More

Nonsurgical Treatment for Localised Hepatocellular Carcinoma

Nonsurgical Treatment for Localised Hepatocellular Carcinoma

May 31, 2016 at 8:26 AM 0 comments

*Andrew Kennedy Radiation Oncology Research, Sarah Cannon Research Institute, Nashville, Tennessee, USA *Correspondence to andrew.kennedy@sarahcannon.com Disclosure: Sirtex Medical are funding a clinical trial at the Sarah Cannon Research Institute. The author has declared no conflicts of interest. Received: 09.12.2015 Accepted: 22.03.16 Citation: EMJ Hepatol. 2016;4[1]:69-75. Abstract The majority of patientsRead More

Fatty Liver Disease: A Crosstalk Between Lipid Species

Fatty Liver Disease: A Crosstalk Between Lipid Species

May 31, 2016 at 8:25 AM 0 comments

*Laura Martinez-Gili,1,2 Carmen Garcia-Ruiz,1-3 Carlos Fernandez-Checa1-3 1. Department of Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain 2. Liver Unit, Hospital Clinic i Provincial de Barcelona, IDIBAPS and CIBERehd, Barcelona, Spain 3. Research Center for ALPD, Keck School of Medicine, University of Southern California,Read More

Immunopathogenesis of Hepatitis B Virus Infection and Related Complications

Immunopathogenesis of Hepatitis B Virus Infection and Related Complications

May 31, 2016 at 8:24 AM 0 comments

*Mankgopo M. Kgatle, Mashiko Setshedi Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa *Correspondence to mankgopo.kgatle@gmail.com Disclosure: The authors have declared no conflicts of interest. Received: 01.02.16 Accepted: 23.03.16 Citation: EMJ Hepatol. 2016;4[1]:84-92. Abstract Chronic hepatitis B (CHB) isRead More

Manifestation of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Different Dietary Mouse Models

Manifestation of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Different Dietary Mouse Models

May 31, 2016 at 8:23 AM 0 comments

*Vera HI Fengler, Tanja Macheiner, Karine Sargsyan Biobank Graz, Medical University of Graz, Graz, Austria. *Correspondence to vera.fengler@medunigraz.at Disclosure: The authors have declared no conflicts of interest. Received: 28.01.16 Accepted: 18.03.16 Citation: EMJ Hepatol. 2016;4[1]:94-102. Abstract Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which are usually associated withRead More

Non-Malignant Portal Vein Thrombosis in Liver Cirrhosis: Diagnosis and Treatment

Non-Malignant Portal Vein Thrombosis in Liver Cirrhosis: Diagnosis and Treatment

May 31, 2016 at 8:22 AM 0 comments

*Tomás Artaza, Miriam Lopes, Marta Romero, Juan José Sánchez, Gema De la Cruz, Concepción González, Rafael Gómez Gastroenterology Department, Hospital Virgen de la Salud, Toledo, Spain *Correspondence to tdeartaza@gmail.com Disclosures: The authors have declared no conflicts of interest. Received: 17.02.16 Accepted: 27.04.16 Citation: EMJ Hepatol. 2016;4[1]:103-110. Abstract Portal vein thrombosisRead More

Treatment Opportunities for Colorectal Liver Metastases

Treatment Opportunities for Colorectal Liver Metastases

April 5, 2016 at 8:49 AM 0 comments

*Tormod Lund Surgical Department, Vestre Viken Hospital Trust, Drammen, Norway. *Correspondence to tolund@vestreviken.no Disclosure: The author has declared no conflicts of interest. Received: 05.02.16 Accepted: 10.03.16 Citation: EMJ. 2016;1[2]:76-83. Abstract Colorectal liver metastases (CLM) are the most common hepatic malignancy and are caused by disseminated tumour cells (DTCs) seeded earlyRead More

Alcoholic Liver Disease: A Comprehensive Review

Alcoholic Liver Disease: A Comprehensive Review

April 5, 2016 at 8:48 AM 0 comments

Partha Pal,1 *Sayantan Ray2 1. Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India 2. Department of Endocrinology, Institute of Post Graduate Medical Education & Research (IPGMER) and SSKM Hospital, Kolkata, India *Correspondence to sayantan.ray30@gmail.com Disclosure: The authors have declared no conflicts of interest. Received: 17.11.15 Accepted: 02.02.16 Citation:Read More

Non-Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure

Non-Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure

April 5, 2016 at 8:47 AM 0 comments

Alabagi Abdulla, Charity Reynolds, *H Hesham A-Kader Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Arizona, Tucson, Arizona, USA *Correspondence to heshamh@aol.com Disclosure: The authors have declared no conflicts of interest. Received: 23.11.15 Accepted: 18.02.16 Citation: EMJ. 2016;1[2]:93-100. Abstract An alarming rise of obesity and, along withRead More

The Role of Sebelipase Alfa in Treating Lysosomal Acid Lipase Deficiency (LAL-D)

The Role of Sebelipase Alfa in Treating Lysosomal Acid Lipase Deficiency (LAL-D)

March 11, 2016 at 9:00 AM 0 comments

Summary of presentations from the Alexion-Sponsored Educators Forum on LAL-D, held in Frankfurt, Germany, on 29th and 30th October 2015 Speakers: Florian Abel,1 Barbara K. Burton,2 Brett Billmeyer3 1. Medical Affairs Europe, Middle-East, Africa, Asia-Pacific, Alexion Pharmaceuticals 2. Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA 3. Afton, Minnesota,Read More